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Abstract To understand modulation of a novel immune-related
cytokine, interleukin-18, by human papillomavirus type (HPV)
16 oncogenes, HaCaT, normal keratinocyte cell line, and C-33A,
HPV-negative cervical cancer cell line, were prepared to
establish stable cell lines expressing E6, E6 mutant (E6m),
E6E7, or E7 constitutively. Expressions of various HPV
oncogene transcripts were identified by RT-PCR. Expression
of HPV oncogene E6 was reversely correlated to the expression
of interleukin-18, a novel pro-inflammatory cytokine. The
expression of E6 in C-33A, independent of E6 splicing, resulted
in decreased IL-18 expression and that of IL-18 was also
significantly reduced in HaCaT cells expressing E6. The level of
p53 was reduced in C-33A cells expressing E6 whereas not
altered in HaCaT cells expressing E6, suggesting that E6
downregulated IL-18 expression via an independent pathway of
p53 degradation in HaCaT cells which have a mutated p53 form.
However, E7 did not affect IL-18 expression significantly in both
C-33A and HaCaT cells. Cotransfection experiments showed
that E6 oncogene did not inhibit the activities of IL-18 promoter
P1 and P2, suggesting that E6 oncogene indirectly inhibited IL-
18 expression. Taken together, E6, E6m and E6/E7 inhibited IL-
18 expression with some variation, assuming that cells expressing
E6 oncogene can evade immune surveillance by downregulating
the expression of immune stimulating cytokine gene, IL-18, and
inhibiting the cascade of downstream effects that follow
activation of the IL-18 receptor. ß 2001 Federation of Euro-
pean Biochemical Societies. Published by Elsevier Science B.V.
All rights reserved.
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1. Introduction
Cervical cancer is one of the leading causes of female death
from cancer worldwide with about 500 000 deaths per year [1].
A strong association between certain human papillomaviruses
(HPVs) (HPV types 16 and 18) and cervical cancer has al-
ready been established [2]. HPVs have circular, double-
stranded DNA genomes that are approximately 8 kb in size
and encode eight genes. Two viral proteins, E6 and E7, are
selectively retained and expressed in carcinoma cells and co-
operated in immortalization of primary keratinocytes [3]. E6
binds to p53, promoting its degradation via ubiquitin medi-
ated proteolysis [4] and increasing genetic instability [5] by
over-riding cell cycle checkpoints for DNA repair. E7 binds
to the retinoblastoma protein (Rb) [6], leading to dissociation
of the E2F-1 transcription factor and activation of genes re-
sponsible for DNA synthesis and cell proliferation [7]. The
host’s in£ammatory and cell mediated immune response serve
important roles in determining whether HPV infections per-
sist, regress or progress [8]. Keratinocytes contribute directly
to the host response by secreting immunoregulatory cytokines
such as interleukin (IL)-1, that recruit and activate leukocytes
at the site of infection. Cervical carcinoma derived cell lines [9]
and keratinocyte cell lines immortalized by HPV-16 demon-
strate altered expression of several immunoregulatory cyto-
kines, suggesting that HPV gene products perturb cytokine
production or secretion [10^12]. Among them, levels of IL-6
and IL-8 are signi¢cantly higher in the cervicovaginal washing
£uid from patients with cervical cancer than those in controls
while the transcription of interferon Q (IFN-Q) gene is signi¢-
cantly reduced in both cervical intraepithelial neoplasia and
cervical cancer tissue as compared to normal cervix [10]. Re-
cently, IL-18 treatment protects mice against acute herpes
simplex virus type 1 infection via both IFN-Q dependent and
independent pathways [13]. However, natural infection is slow
to produce an appropriate therapeutic immune response to
these proteins, probably because HPV has adopted a strategy
to prevent the e¡ective presentation of viral antigens to the
host immune system. Moreover, HPV infection is non-lytic so
there is little release of viral antigen to professional antigen
presenting cells [14]. An optimal therapeutic strategy for ano-
genital HPV infection would be, therefore, to accelerate the
induction of a strong virus speci¢c immune response by in-
ducing local in£ammation and the cytokines necessary to in-
voke HPV speci¢c immunity.
IL-18, initially described as IFN-Q inducing factor (IGIF)
[15], is a pro-in£ammatory cytokine [16]. The cytokine IL-18
possesses pleiotropic biological properties such as activation
of nuclear factor UB (NF-UB) [17], Fas ligand expression
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(FasL) [18], induction of both CC and CXC chemokines [19],
enhancement of the production of IFN-Q and granulocyte
macrophage-colony stimulating factor [20], and induction of
CD4 cytolytic T cell response [21]. In addition, IL-18 enhan-
ces the expression of FasL on NK cells which attack speci¢-
cally cells presenting Fas proteins on membrane but not con-
trol parental cells [22].
Recently, several proteins showing homologs to human and
murine IL-18 binding protein (IL-18BP) were found from
several viruses [23,24]. Molluscum contagiosum virus
(MCV), a human poxvirus, causative agent of papular skin
lesions, persists for a long period without signs of in£amma-
tion, similar to HPV infection. Interestingly, it has been re-
ported that MCV has proteins with high a⁄nity to human
and murine IL-18 proteins and inhibited IL-18 mediated IFN-
Q production [25].
Although there are many suggestions that IFN-Q and cell
mediated immunity are important factors in determining the
progression status of HPV related cervical lesion including
cervical cancer [12,26,27], there is no direct evidence that
high-risk HPV oncoprotein E6 can modulate the function of
IL-18. In this experiment, to investigate in vitro whether the
HPV type 16 E6 and E7 in£uence expression of IL-18, HaCaT
and HPV-negative human cervical cancer cell line C-33A were
stably transfected with E6, E6 mutant (E6m), E6/E7 or E7
gene. The downregulation of IL-18 molecule on protein and
transcriptional levels was observed in transfectants with E6
gene but not in those with E7 gene. In addition, to investigate
whether signi¢cant downregulation of IL-18 is dependent on
direct binding by E6, the interaction between E6 and IL-18
was investigated in an in vitro binding assay and was also
subjected to competition with p53 protein, which has been
known to form a ternary complex with the E6 oncoprotein
and the E6-associated protein (E6AP), leading to its degrada-
tion via the ubiquitin pathway. We also examined whether
high-risk HPV 16 E6 oncoprotein could a¡ect the IL-18 in-
duced IFN-Q production in human PBMCs to elucidate the
possible immune escape mechanisms of HPV infected cervical
lesion including cervical cancer.
2. Materials and methods
2.1. Antibodies and reagents
Monoclonal anti-human IL-18 antibody clone #18-8 (IgG2a) was
made and used as described [28]. Clone #18-8 recognizes both pre-
cursor and mature forms of IL-18. The following were purchased:
anti-human IL-18R antibody, human IL-12p70 and hIL-18 (RpD
system, Minneapolis, MN, USA), hIL-2 (BM, Mannheim, Germany),
Dulbecco’s modi¢ed Eagle’s medium (DMEM), penicillin^streptomy-
cin, amphotericin B and fetal bovine serum (FBS) (Gibco BRL,
Grand Island, NY, USA), OptEIA human IFN-Q ELISA kit (Phar-
Mingen, San Diego, CA, USA), glutathione^Sepharose bead (Amer-
sham Pharmacia Biotech, Little Chalfont, Buckinghamshire, UK), Ni-
nitrilotriacetic acid resin (Qiagen, West Sussex, UK), Immobilon-P
membrane (Millipore, Bedford, MA, USA), goat polyclonal antibod-
ies against C-19 and N-17 of HPV 16 E6 protein (Santa Cruz Bio-
technology, Santa Cruz, CA, USA), mouse anti-human p53 antibody
(Ab-6, Oncogene, Cambridge, MA, USA), BCIP/NBT (Bio-Rad Lab-
oratories, Hercules, CA, USA), Histopaque-1077, polymyxin B,
RPMI 1640, phytohemagglutinin P (PHA), imidazole, phenylmethyl-
sulfonyl £uoride (PMSF), aprotinin, FITC conjugated anti-mouse
IgG, alkaline phosphatase conjugated anti-mouse IgG and horserad-
ish peroxidase conjugated anti-mouse IgG (Sigma, St Louis, MO,
USA). PCR reagents were from Promega (Madison, WI, USA) and
Stratagene (La Jolla, CA, USA). IL-18BP was expressed and puri¢ed
as described [29]. Other reagents were of analytical grade.
2.2. Cell lines
HPV-negative C-33A and HPV-positive cells such as SiHa, CaSki,
and HeLa were purchased from American Type Culture Collection
(Rockville, MD, USA). We also used a spontaneously immortalized
epithelial cell line HaCaT as a control. The cell lines were maintained
in DMEM supplemented with 100 U/ml penicillin^100 Wg/ml strepto-
mycin, and 10% heat-inactivated FBS at 37‡C in a humidi¢ed incu-
bator with 5% CO2. SiHa and CaSki cell lines used in this experiment
have been known to contain 1 or 2 and 60^600 copies of HPV 16
type, respectively [30,31]. HeLa cells have been reported to harbor 10^
50 copies of HPV 18 type by which carcinoma is induced [32]. C-33A
cells are cervical carcinoma derived from other causes than HPV in-
fection [33]. Human PBMC used in these experiments were obtained
from fresh whole blood of healthy volunteers after informed consent
or from packed red cell purchased from Chung-Nam National Blood
Bank (Taejon, South Korea). PBMC were isolated from bu¡y coat of
heparinized whole blood or citrate^phosphate^dextrose treated
packed red cells by centrifugation on a density gradient of Histo-
paque-1077, then washed three times with phosphate bu¡ered saline
(PBS). PBMC were suspended at a ¢nal concentration of 1U106 cells/
ml in RPMI 1640 medium supplemented with 100 U/ml penicillin^100
Wg/ml streptomycin, 25 ng/ml amphotericin B, 10% heat-inactivated
FBS and 50 WM of 2-mercaptoethanol and cultured at 37‡C in a
humidi¢ed incubator with 5% CO2.
2.3. Preparation of expression vectors for E6, E6m, E7, E6/E7
The CaSki cells were derived from a cervical carcinoma and con-
tained integrated HPV 16 genomes. E6, E6/E7 and E7 were made by
PCR ampli¢cation from total RNA isolated from CaSki cell lines
using following primer pairs: 5P-GCG GCC GCC ACC ATG TTT
CAG GAC CAC AG-3P (sense) and 5P-CTG CGG CCG CGA TTA
CAG CTG GGT TTT CTC T-3P (antisense); 5P-GCG GCC GCC
ACC ATG TTT CAG GAC CAC AG-3P (sense) and 5P-AGG
CGG CCG CGA TTA TGG TTT CTG AGA ACA-3P (antisense);
5P-GCG GCC GCC ACC ATG GCA TGG CAT GGA GAT ACA
CCT-3P (sense) and 5P-AGG CGG CCG CGA TTA TGG TTT CTG
AGA ACA-3P (antisense). The PCR products were inserted into
PCR02.1-TOPO cloning vector (Invitrogen, Carlsbad, CA, USA) or
T vector, which had been prepared from pBluescript KS(+) (Invitro-
gen, Carlsbad, CA, USA) according to the method of Marchuk et al.
[34] as an intermediate step for subcloning into corresponding expres-
sion vector. In brief, either E6 or E7 gene containing NotI was ligated
into pOP|3 which was prepared by digesting pOP|3CAT1 (Strata-
gene, La Jolla, CA, USA) with NotI to remove CAT gene and de-
phosphorylated with calf intestinal alkaline phosphatase for prevent-
ing self-ligation. E6/E7 gene, which excised from PCR02.1-TOPO
vector by digestion with EcoRI, was ligated into pTARGET (Prom-
ega, Madison, WI, USA) in forward direction to construct pTAR-
GET/E6E7. E6m was prepared according to the procedure by Shira-
sawa et al. [35]. Brie£y, for expression of full length E6, E6m was
ampli¢ed by sequential PCR using speci¢cally designed primer sets
such as sense primer, antisense primer and mutagenic primers con-
taining two mismatches in splicing donor sites located within the E6
ORF. Two partial E6 inserts with overlapped regions were ampli¢ed
by PCR using pOP|3/E6 as template and combined primer sets of
either E6 sense primer (5P-GAA GAT CTC TAT GTT TCA GGA
CCA CAG-3P) and antisense mutagenic primer (217^236) (5P-AGT
CAT ATA GCT CGC GTC GC-3P) or (5P-GCG ACG CGA GCT
ATA TGA CT-3P) sense mutagenic primer and E6 antisense primer
(5P-TTA CAG CTG GGT TTT CTC T-3P). The resulting PCR prod-
ucts were mixed, denatured and annealed slowly after addition of E6
sense and antisense primers. Second PCR was performed for complet-
ing full length E6m that is not subjected to be splicing. PCR product
was subcloned into PCR 2.1TOPO vector to construct TOPO/E6m.
E6m, excised from BglII/SalI, was inserted into mammalian expres-
sion vector pTARGET to express the full length E6. Their expressions
in transfectants were identi¢ed by reverse transcription-polymerase
chain reaction (RT-PCR) using speci¢c primers due to the low levels
of protein expression.
2.4. Establishment of stable transfectants
Cells grown in DMEM were prepared to establish stable cell line
expressing oncogenes. Transfection was performed using SuperFect1
(Qiagen, Germany) according to the manufacturer’s instructions.
Brie£y, C-33A and HaCaT cells were seeded in 6 cm dishes to reach
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70% con£uence at 24 h. Medium was then removed, and complex of
30 Wl SuperFect and 5 Wg DNA was directly transferred to the cells.
After the plate was incubated for 2 h at 37‡C and 5% CO2, medium
containing the remaining complexes was removed, and replaced with
fresh cell growth medium. Cells were allowed to incubate for 48 h,
followed by growing in selective DMEM medium containing G-418
(800 Wg/ml) (Gibco BRL) for 2 months. G418 resistant colonies were
pooled for each cell population.
2.5. RT-PCR
RT-PCR was carried out to identify expression of E6, E7 and E6/
E7 from total RNA isolated from stable transfectants according to the
manufacturer’s instructions (Stratagene). In brief, the cDNA was syn-
thesized from total RNA in 50 Wl reaction volume containing 5 Wl
10U ¢rst-strand bu¡er, 1 Wl RNase block ribonuclease inhibitor (40
U/Wl), 2 Wl 100 mM dNTPs and 1 Wl MMLV-RT (50 U/Wl) and
mixtures were gently incubated at 37‡C for 1 h. The resulting
cDNA was ampli¢ed using E6 and E7 speci¢c primers as describe
above under following PCR cycles (30 cycles: 1 min at 95‡C, 1 min
at 57‡C and 1 min 30 s at 72‡C). The PCR products were analyzed on
1% agarose gel. The primers for IL-18 were based on the published
sequence of human IL-18 [20] : 5P-CAT GCC ATG GCT GCT GAA
CCA GTA GAA GA-3P (sense) and 5P-CGG GAT CCA ATA GCT
AGT CTT CGT TTT G-3P (antisense). The primer sequences for L-
actin as an internal standard were 5P-GTG GGG CGC CCC AGG
CAC CA-3P (sense) and 5P-CTC CTT AAT GTC ACG CAC GAT
TTC-3P (antisense).
2.6. Northern blot
To prepare Northern probe for IL-18, its cDNA was synthesized by
RT-PCR using primers described above. IL-18 cDNA was labelled
with random priming and used as a probe. Total cellular RNA was
extracted from C-33A cells expressing E6 or E7 using the RNAzol B
reagent (Tel-Test, Friendswood, TX, USA) according to the manu-
facturer’s instructions. RNA samples (20 Wg) were separated on 1.2%
agarose/formaldehyde gels and transferred to nylon membranes. The
¢lter was hybridized with radiolabelled IL-18 cDNA probe, washed
and autoradiographed at 370‡C.
2.7. Plasmid constructs and expressions of proteins for E6, IL-18 and
p53
E6 gene was ampli¢ed by PCR from total RNA isolated from
CaSki cell lines as described above. E6 insert from pBluescript
KS(+)/E6 was inserted into BamHI^SalI site of PET28a (Novagen,
Madison, WI, USA) as described [36]. IL-18 gene was synthesized
using total RNA from normal keratinocyte cell line, HaCaT. The
primers for mature hIL-18 were the following: 5P-CGC GGA TCC
TAC TTT GGC AAG-3P (sense), 5P-CCG GAA TTC AAT AGC
TAG TCT TCG-3P (antisense). After subcloning the IL-18 PCR prod-
ucts into T vector which had been prepared from pBluescript KS(+),
and con¢rming IL-18 sequence, mature IL-18 was subcloned into
BamHI^SalI site of pET28a. Construction of the p53 was carried
out by RT-PCR using total RNA extracted from HaCaT and the
following primer pairs with enzyme site italicized: 5P-GGA ATTCCA-
TATGGA GGA GCCGCAGTCAGATCC-3P (sense), 5P-CGGGATC-
C TCA GTC TGAGTCAGGCCCTT-3P (antisense). PCR product
was digested with NdeI and BamHI and cloned into the corresponding
sites of plasmid pET3a (Novagen). Histidine fusion proteins were ex-
pressed in Escherichia coli BL21 (DE3) using pET28/E6,/IL-18 and
puri¢ed with Ni-nitrilotriacetic acid resin as described [37]. The eluted
proteins were identi¢ed by Western blot analysis using corresponding
primary antibodies and alkaline phosphatase conjugated secondary
antibodies (anti-goat antibody and anti-mouse antibody). BCIP/
NBT was used as a substrate for color development. The protein
concentration was determined by Bradford method. Then the puri¢ed
proteins were aliquoted and stored at 370‡C until use.
2.8. The e¡ect of p53 on the binding between E6 and IL-18
E6 insert was excised from digestion of pBluescript KS(+) (Strata-
gene, La Jolla, CA, USA)/E6 with BamHI/SalI and subcloned into
corresponding expression vectors pGEX4T-1 (Amersham Pharmacia
Biotech AB, Uppsala, Sweden) which had been prepared by digesting
with BamHI/SalI. Transformation of pGEX/E6 into DH5K was per-
formed to express GST-fused E6. pGEX/E6 was expressed in DH5K,
prepared in PBS containing 0.5% Triton X-100 and then sonicated.
The resulting lysates were centrifuged for 30 min at 12 000 rpm to
remove the pellet containing cell debris. Supernatants were used as
cell lysate for binding assay. Binding assays were performed by com-
bining GST^E6 immobilized on GSH^Sepharose with increasing
doses of lysates containing His-tagged IL-18 protein ranging from
5 to 800 Wg in binding bu¡er, PBS containing 0.5% Triton X-100.
The mixtures were rotated in microcentrifuge tubes at 4‡C for 1 h.
The beads were washed three times with binding bu¡er, and then
boiled for 5 min in 50 Wl of SDS gel loading bu¡er. The proteins
solubilized in the sample bu¡er were subjected to electrophoresis on
a 12% polyacrylamide gel, transferred to membrane and immunoblot-
ted using an antibody that speci¢cally recognizes IL-18. To investigate
whether p53 inhibited the binding between E6 and IL-18, increasing
doses of lysates containing p53 protein were incubated with binding
mixtures of E6 and IL-18.
2.9. Immunoblotting analysis
Cells from 10 cm dishes were lysed in lysis bu¡er containing pro-
tease inhibitor aprotinin (10 Wg/ml) and 0.5 mM PMSF. The protein
concentration in the lysate was determined with Bradford assay, and
equal amounts of protein (50 Wg) from each lysate were electropho-
resed on 12.5% polyacrylamide SDS gels. Proteins were transferred
onto Immobilon-P membrane. p53 and IL-18 were detected with the
monoclonal anti-p53 antibody and monoclonal anti-IL-18 antibody
#18-8 (IgG2a), respectively. Proteins were visualized by adding a sub-
strate BCIP/NBT for alkaline phosphatase conjugated to secondary
antibody.
2.10. Transient transfection and CAT assay
HaCaT and C-33A cells were cotransfected with pOP|3/E6 and IL-
18 promoter pCAT-p1-2688 or pCAT-p2-2.3 plasmid [38] by using
SuperFect1 (Qiagen, Germany) according to the manufacturer’s in-
structions. After 6 h, cells were washed twice with PBS and fresh
complete medium was added to the cells. About 24 h later, the cells
were washed with ice-cold PBS, resuspended in 0.25 M Tris (pH 7.8),
and subjected to three cycles of freezing and thawing. Cell lysates were
heated for 10 min to inactivate CAT inhibitors and then assayed for
CAT enzyme activity by TLC method [39]. As a control, cells were
cotransfected with pCH110 plasmid (Pharmacia, Piscataway, NJ,
USA) for L-galactosidase activity.
2.11. IFN-Q assay
Human PBMCs in RPMI medium were seeded into 96 well plates
in 200 Wl at ¢nal concentrations of 1U106/ml and 5U105/ml, respec-
tively, and pretreated with 10 Wg/ml polymyxin B to neutralize endo-
toxins. Human IL-18 was used as an inducing agent and PHA as a
costimulator in PBMC. For recombinant E6 protein from E. coli was
assessed whether it could inhibit the IFN-Q production by IL-18. The
E6 protein or neutralizing antibody were mixed with IL-18, preincu-
bated at room temperature for 30 min, and treated in PBMCs for 20 h,
and the secreted IFN-Q was measured with an IFN-Q ELISA kit ac-
cording to the manufacturer’s instructions.
Fig. 1. Identi¢cation of IL-18 expression by Western blot analyses
in cervical cancer cell lines. 50 Wg of proteins extracted from each
indicated cell lines were separated on SDS/12% polyacrylamide gel
and electroblotted to an Immobilon-P membrane. The IL-18 was
detected with mouse monoclonal anti-hIL-18 antibody #18-8
(IgG2a). The bound anti-IL-18 antibody was detected by alkaline-
phosphatase conjugated secondary antibody followed by NBT/BCIP
substrate for development.
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2.12. Statistical analysis
ANOVA using Fisher’s least signi¢cant di¡erence was used. Data
were expressed as the mean þ S.D.
3. Results
3.1. IL-18 expression was downregulated in cervical cancer cell
lines HeLa and CaSki which represent for HPV type 18
and HPV type 16 infection, respectively
We preliminary surveyed the expression levels of IL-18 in
cervical cancer cell lines and normal keratinocyte HaCaT
cells. Western blot analyses showed that IL-18 expression level
was strong in HaCaT and moderate in C-33A and SiHa har-
boring 1 or 2 copies of HPV 16while IL-18 protein was not
detected in HeLa and CaSki harboring 10^50 copies of HPV
type 18 and 60^600 copies of HPV type 16 genome, respec-
tively (Fig. 1). Our data revealed that the expression of IL-18
was signi¢cantly downregulated in HPV-positive cervical can-
cer cell lines when compared to HaCaT and C-33A, suggest-
ing that HPV infection may be correlated to the IL-18 expres-
sion.
3.2. Expression levels of both IL-18 and p53 were decreased in
C-33A cells expressing E6 oncogene
In order to address the correlation between HPV infection
and IL-18 expression level, representative oncogenes E6 and
E7 of HPV were stably transfected into non-cervical cell line
HaCaT, and HPV-negative cervical cancer cell line C-33A. As
shown in Fig. 2, the expressions of E6, E6m, E7 and E6/E7
were con¢rmed in respective transfectants by RT-PCR. As
previously reported [40], most of E6 transcripts were in the
spliced form E6*I, and full length E6 and the other spliced
form E6*II were detected in small amounts while E6m, bear-
ing a point mutation in the splice donor, failed to produce the
truncated E6. The expression pattern of E6/E7 was similar to
that of E6 but the untruncated E6 level was higher than other
truncated E6 species. It has been well known that E6 protein
forms complexes with p53 [41,42] and can target p53 for deg-
radation through the ubiquitin dependent pathway [1]. The
functional activity of E6 expression in transfectants was de-
Fig. 2. The identi¢cation of E6 and E7 expression in C-33A and HaCaT cells stably transfected with E6, E6m, E6/E7 and E7. E6 and E7 ex-
pression in transfectants were detected by RT-PCR using total RNA and combined primer sets as described in Section 2. M: molecular weight
marker as in Fig. 3.
Fig. 3. Immunoblot analysis (A) of IL-18 and p53 in stable transfec-
tants C-33A and HaCaT keratinocytes expressing E6 and E7 onco-
genes, Northern blot (B) and RT-PCR (C) analyses of IL-18
mRNA level in C-33A cells expressing E6 or E7 oncogenes. Prepa-
rations of protein lysate and mRNA, electrophoresis, transfer, prob-
ing and RT-PCR were performed as described in Section 2. The IL-
18 and p53 were detected with monoclonal anti-hIL-18 antibody
#18-8 (IgG2a) and mouse anti-human p53 antibody, respectively.
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termined by degradation of endogenous p53 protein (Fig. 3A).
In order to investigate whether E6 could inhibit the expression
of IL-18 mRNA, the levels of IL-18 mRNA were identi¢ed by
Northern blot and RT-PCR, showing that IL-18 mRNA was
decreased by E6 transfection (Fig. 3B,C). The p53 protein in
C-33A cells expressing E6 was sensitive to degradation where-
as E6 expressed in HaCaT cells did not a¡ect p53 in terms of
its degradation (Fig. 3A). As similar to downregulation of
p53, C-33A cells expressing E6 decreased the IL-18 expression
signi¢cantly, and transfectants with E6/E7 or E6m inhibited
its expression a little. In case of HaCaT cells, similar results
were observed with C-33A cells transfected with E6, E6/E7
and E6m with respect to the IL-18 expression level. However,
irrespective of E6 expression, levels of p53 in HaCaT were
signi¢cantly una¡ected.
3.3. IL-18 was competitively bound to E6 with p53
In order to investigate whether IL-18 bound to E6, we
tested the in vitro binding assay using recombinant GST-fused
E6 and recombinant mature IL-18. As shown in Fig. 4, IL-18
was able to bind to E6 immobilized on GSH^Sepharose beads
(Fig. 4A) and its binding was a little bit inhibited by addition
of p53 (Fig. 4B), suggesting that IL-18 could bind to the p53
binding site of E6. In binding experiments for GST-fused E6,
we used total cell lysates which contain either overexpressed
p53 or IL-18 and a lots of other proteins. So, we added excess
of proteins to bead-bound proteins for interaction.
3.4. IL-18 promoters were not inhibited by E6
In order to investigate how IL-18 expression was inhibited
by E6, we cotransfected HaCaT and C-33A cells with pOP|3/
E6 and IL-18 promoter pCAT-p1-2688 or pCAT-p2-2.3 plas-
mid. As shown in Fig. 5, E6 oncogene did not a¡ect the
activities of IL-18 promoter P1 and P2, suggesting that E6
downregulated IL-18 independent of the IL-18 promoter.
Fig. 5. E¡ects of E6 on p1 and p2 promoter activation of IL-18.
HaCaT and C-33A cells were cotransfected with 1 Wg or 5 Wg of
p1-2686 (p1 promoter) or p2-2.3 (p2 promoter) plasmid derived
from IL-18 promoter and 1 Wg of L-galactosidase expression vector
(pCH110), together with increasing amounts (Wg) of E6 expression
vector or control vector. After 24 h, CAT activities normalized by
L-galactosidase activity were determined. The values are shown as
mean þ S.D. from three independent experiments with similar re-
sults.
Fig. 4. Interaction of E6 with IL-18 in vitro binding assay and com-
petitive inhibition of E6-IL-18 binding by p53 protein. A: The en-
tire coding sequence of HPV 16 E6 was fused in frame with GST
and resultant product GST^E6 was immobilized on GSH^Sepharose
bead. Increasing lysates of bacterially expressed IL-18 were incu-
bated with a puri¢ed GST^E6 fusion protein or with GST alone
(control) bound to beads. IL-18 bound to E6 was analyzed by
SDS^PAGE on a 12.5% gel followed by Western blot analysis using
monoclonal anti-hIL-18 antibody #18-8 (IgG2a). B: Constant
amount of his-tagged IL-18 and increasing doses of p53 were incu-
bated with a puri¢ed GST^E6 fusion protein bound to bead. IL-18
or p53 bound to E6 was analyzed by SDS^PAGE followed by
Western blotting using monoclonal anti-IL-18 antibody #18-8 or
mouse anti-human p53 antibody, respectively. 1, p53 (1/10 dilution);
His IL-18 (1/10 dilution); 2, bead GST E6+His IL-18 (80 Wl) ;
3, bead GST E6+His IL-18 (80 Wl)+p53 200 Wg; 4, bead GST
E6+His IL-18 (80 Wl)+p53 400 Wg; 5, bead GST E6+p53 400 Wg.
Fig. 6. The e¡ect of HPV oncoprotein E6 on IL-18 induced IFN-Q
production in PBMCs. Polymyxin B (10 Wg/ml) was added into the
cells to neutralize endotoxin. The concentrations of the reagents
used were as follows; IL-18 (50 ng/ml), PHA (1 Wg/ml), neutralizing
anti-IL-18R antibody (0.5 Wg/ml). The oncoproteins or neutralizing
antibody were mixed with IL-18, preincubated at room temperature
for 30 min, and treated into PBMCs for 20 h. This result represents
one of ¢ve experiments. The values are shown as mean þ S.D. from
triplicates. P6 0.05 compared to cells treated with both IL-18 and
PHA.
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3.5. HPV 16 E6 oncoprotein inhibited IL-18 induced
IFN-Q production
Because E6 downregulated IL-18, we also investigated
whether HPV 16 E6 oncoprotein could inhibit IL-18 induced
IFN-Q production in PBMC from ¢ve di¡erent donors. The
e¡ect of IL-18 on IFN-Q production was con¢rmed by neu-
tralizing anti-human IL-18R antibody treatment. IL-18 usu-
ally induces IFN-Q in the presence of mitogen or with combi-
nation of IL-12 treatment. The coincubation of E6 protein
and IL-18 showed a signi¢cant decrease in IL-18 induced
IFN-Q production in PHA treated PBMCs (Fig. 6).
4. Discussion
It has been reported that there is a reduction in the expres-
sion levels of type 1 cytokines in HPV induced cervical lesions
[10,43]. We investigated the correlation between HPV infec-
tion and expression level of type 1 cytokine IL-18. Represen-
tative oncogenes E6 and E7 of HPV were stably transfected
into HPV-negative cervical cancer cell line C-33A (Fig. 2).
The HPV 16 polycistronic mRNA transcribed from E6 and
E7 ORFs initiate from the p97 early promoter [39]. E6 gene
encodes, in addition to the full length E6 open reading frame
(ORF: 450 bp), truncated E6 ORFs (E6*I (300 bp) and E6*II
(150 bp)) which are generated as a result of di¡erential splic-
ing [35,44]. In cervical carcinoma tissues, premalignant le-
sions, and cell lines derived from cervical cancer the E6*I
encoding mRNA is a major transcript. Whenever we perform
RT-PCR with RNAs extracted from CaSki, SiHa and C-33A
transfectants expressing E6/E7, an additional band appears
over the full length E6. As mentioned in Section 2, E6/E7
gene in HPV-containing cells such as CaSki and SiHa is ex-
pressed as a bicistron and processed into splicing, resulting in
E6*I/E7 and E6*II/E7 as well as E6/E7. Therefore, by inter-
action of PCR primers speci¢c for E6 with E7 sequence fol-
lowing E6, additional larger products are non-speci¢cally gen-
erated under our RT-PCR condition. mRNA species for E6
can be designated on the basis of migration patterns which
correspond to those for PCR products obtained from respec-
tive cDNAs under the same condition. Similar migration pat-
terns were shown in a previous report [40]. C-33A cells trans-
fected with E6 decreased signi¢cantly the IL-18 expression,
and transfectants with E6/E7 or E6m inhibited its expression
a little as well as downregulation of p53 (Fig. 3A). As pre-
viously reported [40], C-33A cells transfected by E6 showed
that most of E6 transcripts were spliced form E6*I, which
might be essential for degradation of mutant p53, tumor sup-
pressor protein. E6 expression in C-33A leads to degradation
of mutant p53 (Fig. 3A), while levels of p53 in HaCaT cells
expressing E6 remains constant, indicating that mutant p53
present in HaCaT cells is insensitive to the E6 targeted deg-
radation via the ubiquitin pathway. This result was also pre-
viously reported [45].
Similar to precursor IL-1L (proIL-1L), precursor IL-18
(proIL-18) does not contain a signal peptide required for
the removal of the precursor amino acids with subsequent
secretion. The activity of the precursor is exceedingly low,
but after cleavage by caspase-1, the mature form is fully ac-
tive. In addition to caspase-1, caspase-3, though being likely
to play a greater role in cell death, cleaves mature or proIL-18
after aspartic acid 71 and 76, resulting in inactive peptides
[46]. Thus, proIL-18 may serve as a negative regulator of
Fas mediated cell death by acting as a sink for the enzymatic
activity of caspase-1 and caspase-3. IL-18 administration to
mice as an adjuvant provided enhanced NK cell activation
[21] and IL-18 may possess host-defense functions independ-
ent of IFN-Q [47]. Pre- and early treatment with IL-18 reduced
infection severity, prolonged life via increase of innate defense
against tumors [48,49].
In this study, to elucidate whether IL-18 was a¡ected by
HPV oncogenes, stable cell lines expressing HPV 16 E6 or E7
in C-33A and HaCaT cells were established. Our data re-
vealed that p53 and IL-18 were less expressed in HPV-positive
cell lines CaSki and HeLa whereas HPV-negative cell lines
HaCaT and C-33A cells expressed p53 and IL-18 at high
levels. The expression of E6 in HaCaT and C-33A cell lines
was reversely correlated to the expression of IL-18, assuming
that HPV infection can evade immune surveillance by down-
regulating the expression of immune stimulating cytokine.
Our experiment was focused to investigate how IL-18 was
modulated by E6. In vitro binding experiments showed that
his-tagged mature IL-18 bound to GST^E6 (Fig. 4), suggest-
ing that once IL-18 bound to E6, IL-18 might be degraded by
E6 via the ubiquitin pathway or any other pathways. The
partial competitive inhibition of IL-18 bound to E6 by p53
protein at a high concentration suggests that either the bind-
ing domain on E6 protein may be shared by both p53 and IL-
18 or structural changes in E6 responsible for IL-18 binding
may be induced by p53 binding to E6. We also cotransfected
C-33A and HaCaT with both IL-18 promoters and E6 to
elucidate whether E6 oncogene could inhibit IL-18 promoters
(Fig. 5). These cotransfection experiments showed that there
was no e¡ect of E6 on the activities of IL-18 promoter p1 and
p2, suggesting that E6 oncogene downregulated IL-18 indi-
rectly. The decrease of IL-18 levels by E6 and interaction of
IL-18 with E6 may interfere with the local in£ammatory pro-
cess caused by the cascade of downstream e¡ects that follow
activation of the IL-18 receptor via binding to IL-18. Simi-
larly, a family of proteins encoded by MCV is able to bind
with high a⁄nity to human and murine IL-18 molecules and
inhibited IL-18 mediated IFN-Q production in a dose depen-
dent manner [25]. IL-18 has been shown to protect mice
against herpes simplex virus infection by IFN-Q dependent
and independent pathways [13]. Although the role of IL-18
on HPV pathogenesis has not been determined yet, the bind-
ing of the IL-18 to E6 is not only bene¢cial to viral infection
with respect to the critical role of IL-18 in defense against
virus but also provides a mechanism for evasion of the im-
mune system by HPV. Additional studies are under way to
further elucidate the downregulatory mechanism of IL-18 by
E6 and the role of IL-18 in the local immunity of cervical
mucosa against HPV-related cervical lesions.
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